All In Biotech

Drug Trial Radar · NCT05653271

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 21, 2023

Primary completion

Mar 31, 2026

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Acepodia Biotech, Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

Conditions

  • B-cell Lymphoma
  • Non Hodgkin Lymphoma
  • DLBCL
  • Primary Mediastinal Large B Cell Lymphoma
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Burkitt Lymphoma
  • High-grade B-cell Lymphoma

Interventions

  • CyclophosphamideDrug

    Lymphodepleting agent

  • FludarabineDrug

    Lymphodepleting agent

  • ACE1831Drug

    Allogeneic gamma delta T (gdT) cell therapy

  • ObinutuzumabDrug

    Anti-CD20 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: 2 years
  2. Change from baseline in ECOG statusTime frame: 1 year
  3. Change from baseline in physical examination resultsTime frame: 1 year
  4. Change from baseline clinical laboratory tests resultsTime frame: 1 year
  5. Change from baseline in urinalysis resultsTime frame: 1 year
  6. Change from baseline in vital signs resultsTime frame: 1 year
  7. Change from baseline in electrocardiogram (ECG) resultsTime frame: 1 month
  8. Maximum Tolerated Dose (MTD)Time frame: 1 month

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • AdventHealth Orlando

    Orlando, Florida

  • Emory University

    Atlanta, Georgia

  • Indiana University Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Queen Mary Hospital

    Hong Kong, Hong Kong, Hong Kong

  • Tamsui MacKay Memorial Hospital

    New Taipei City, Taiwan

  • Linkou Chang-Gung Memorial Hospital

    Taoyuan City, Taiwan

  • Kaohsiung Chang-Gung Memorial Hospital

    Kaohsiung City, Kaohsiung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

  • Ministry of Health and Welfare Shuang-Ho Hospital

    New Taipei City, Taiwan, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.